Pluristyx announced a license agreement with Humacyte, Inc. Humacyte has licensed Pluristyx's clinical-grade PluriBank induced Pluripotent Stem Cell (iPSC) line as starting materials for manufacturing insulin-producing cells for their BioVascular Pancreas (BVP) product candidate. This partnership includes access to Pluristyx's revolutionary panCELLa?? platform that enables the generation of "hypoimmune" cells for clinical implantation.

PluriBank?? iPSCs are derived from regulatory-compliant donors, extensively characterized, and expanded and banked to provide purity, identity, and genetic integrity for patient safety, available with custom edits and Pluristyx's proprietary FailSafe®? and iACT??

edits with a goal of providing improved safety and efficacy. The License Agreement grants Humacyte access to pluristyx's PluriBank?? cell lines for application in their BioVascular PancreAS development program.

Pluristyx is also performing custom clinical gene editing on the iPSC line to generate a universally applicable line for all patients. The BVP is designed to revolutionize type 1 diabetes treatment by enabling delivery and survival of insulin-producing islets inside the body. The Acellular Tissue Engineered Vessel and the BVP are investigational products and have not been approved for sale by the Food and Drug Administration or any international regulatory agency.